[1]
|
Crawford, J., Dale, D.C. and Lyman, G.H. (2004) Chemotherapy-Induced Neutropenia: Risks, Consequences, and New Directions for Its Management. Cancer, 100, 228-237. https://doi.org/10.1002/cncr.11882
|
[2]
|
Ouyang, Z., Peng, D. and Dhakal, D.P. (2013) Risk Factors for Hematological Toxicity of Chemotherapy for Bone and Soft Tissue Sar-coma. Oncology Letters, 5, 1736-1740. https://doi.org/10.3892/ol.2013.1234
|
[3]
|
Li, M., Li, X., Guo, Y., Miao, Z., Liu, X., Guo, S. and Zhang, H. (2020) Development and Assessment of an Individualized Nomogram to Predict Colo-rectal Cancer Liver Metastases. Quantitative Imaging in Medicine and Surgery, 10, 397-414. https://doi.org/10.21037/qims.2019.12.16
|
[4]
|
Stern, A.C. and Jones, T.C. (1992) The Side-Effect Profile of GM-CSF. Infection, 20, S124-S127.
https://doi.org/10.1007/BF01705031
|
[5]
|
Ushach, I. and Zlotnik, A. (2016) Biological Role of Granulocyte Mac-rophage Colony-Stimulating Factor (GM-CSF) and Macrophage Colony-Stimulating Factor (M-CSF) on Cells of the Myeloid Lineage. Journal of Leukocyte Biology, 100, 481-489. https://doi.org/10.1189/jlb.3RU0316-144R
|
[6]
|
Mehta, H.M., Malandra, M. and Corey, S.J. (2015) G-CSF and GM-CSF in Neutropenia. Journal of Immunology, 195, 1341-1349. https://doi.org/10.4049/jimmunol.1500861
|
[7]
|
Stinchcombe, T.E. and Gore, E.M. (2010) Limited-Stage Small Cell Lung Cancer: Current Chemoradiotherapy Treatment Paradigms. The Oncologist, 15, 187-195. https://doi.org/10.1634/theoncologist.2009-0298
|
[8]
|
Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W.J., Fu-ruse, K., Fournel, P., Belderbos, J., Clamon, G., Ulutin, H.C., Paulus, R., et al. (2010) Meta-Analysis of Concomitant versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 28, 2181-2190.
https://doi.org/10.1200/JCO.2009.26.2543
|
[9]
|
Joshi, S.S. and Badgwell, B.D. (2021) Current Treatment and Re-cent Progress in Gastric Cancer. CA: A Cancer Journal for Clinicians, 71, 264-279. https://doi.org/10.3322/caac.21657
|
[10]
|
Schrag, D., Shi, Q., Weiser, M.R., Gollub, M.J., Saltz, L.B., Musher, B.L., Goldberg, J., Al Baghdadi, T., Goodman, K.A., McWilliams, R.R., et al. (2023) Preoperative Treatment of Locally Ad-vanced Rectal Cancer. The New England Journal of Medicine, 389, 322-334. https://doi.org/10.1056/NEJMoa2303269
|
[11]
|
Versteijne, E., van Dam, J.L., Suker, M., Janssen, Q.P., Groothuis, K., Akkermans-Vogelaar, J.M., Besselink, M.G., Bonsing, B.A., Buijsen, J., Busch, O.R., et al. (2022) Neoadjuvant Chemoradiotherapy versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. Journal of Clinical Oncology, 40, 1220-1230. https://doi.org/10.1200/JCO.21.02233
|
[12]
|
Tang, L.L., Guo, R., Zhang, N., Deng, B., Chen, L., Cheng, Z.B., Huang, J., Hu, W.H., Huang, S.H., Luo, W.J., et al. (2022) Effect of Radiotherapy Alone vs Radiotherapy with Concur-rent Chemoradiotherapy on Survival without Disease Relapse in Patients with Low-Risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial. JAMA, 328, 728-736. https://doi.org/10.1001/jama.2022.13997
|
[13]
|
Klastersky, J., de Naurois, J., Rolston, K., Rapoport, B., Maschmeyer, G., Aapro, M. and Herrstedt, J. (2016) Management of Febrile Neutropaenia: ESMO Clinical Practice Guidelines. Annals of Oncology, 27, v111-v118.
https://doi.org/10.1093/annonc/mdw325
|
[14]
|
Asna, N., Livoff, A., Batash, R., Debbi, R., Schaffer, P., Rivkind, T. and Schaffer, M. (2018) Radiation Therapy and Immunotherapy—A Potential Combination in Cancer Treatment. Current Oncology, 25, 454-460.
https://doi.org/10.3747/co.25.4002
|
[15]
|
Takeshima, T., Pop, L.M., Laine, A., Iyengar, P., Vitetta, E.S. and Hannan, R. (2016) Key Role for Neutrophils in Radiation-Induced Antitumor Immune Responses: Potentiation with G-CSF. Pro-ceedings of the National Academy of Sciences of the United States of America, 113, 11300-11305. https://doi.org/10.1073/pnas.1613187113
|
[16]
|
Liu, Y., Dong, Y., Kong, L., Shi, F., Zhu, H. and Yu, J. (2018) Abscopal Effect of Radiotherapy Combined with Immune Checkpoint Inhibitors. Journal of Hematology & Oncology, 11, Article No. 104.
https://doi.org/10.1186/s13045-018-0647-8
|
[17]
|
Leary, R., Gardner, R.B., Mockbee, C. and Roychowdhury, D.F. (2019) Boosting Abscopal Response to Radiotherapy with Sargramostim: A Review of Data and Ongoing Studies. Cu-reus, 11, e4276. https://doi.org/10.7759/cureus.4276
|
[18]
|
Aliru, M.L., Schoenhals, J.E., Venkatesulu, B.P., An-derson, C.C., Barsoumian, H.B., Younes, A.I., Ls, K.M., Soeung, M., Aziz, K.E., Welsh, J.W., et al. (2018) Radiation Therapy and Immunotherapy: What Is the Optimal Timing or Sequencing? Immunotherapy, 10, 299-316. https://doi.org/10.2217/imt-2017-0082
|
[19]
|
Mouchemore, K.A. and Anderson, R.L. (2021) Immunomodulatory Effects of G-CSF in Cancer: Therapeutic Implications. Seminars in Immunology, 54, Article ID: 101512. https://doi.org/10.1016/j.smim.2021.101512
|
[20]
|
Kumar, A., Taghi Khani, A., Sanchez Ortiz, A. and Swaminathan, S. (2022) GM-CSF: A Double-Edged Sword in Cancer Immunotherapy. Frontiers in Immunology, 13, Article 901277. https://doi.org/10.3389/fimmu.2022.901277
|
[21]
|
Bhattacharya, P., Budnick, I., Singh, M., Thiruppathi, M., Alhar-shawi, K., Elshabrawy, H., Holterman, M.J. and Prabhakar, B.S. (2015) Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy. Journal of Interferon & Cytokine Research, 35, 585-599. https://doi.org/10.1089/jir.2014.0149
|
[22]
|
van de Laar, L., Coffer, P.J. and Woltman, A.M. (2012) Regulation of Dendritic Cell Development by GM-CSF: Molecular Control and Implications for Immune Homeostasis and Therapy. Blood, 119, 3383-3393.
https://doi.org/10.1182/blood-2011-11-370130
|
[23]
|
Bhattacharya, P., Thiruppathi, M., Elshabrawy, H.A., Alhar-shawi, K., Kumar, P. and Prabhakar, B.S. (2015) GM-CSF: An Immune Modulatory Cytokine That Can Suppress Au-toimmunity. Cytokine, 75, 261-271.
https://doi.org/10.1016/j.cyto.2015.05.030
|
[24]
|
Xu, S., Höglund, M., Hâkansson, L. and Venge, P. (2000) Granu-locyte Colony-Stimulating Factor (G-CSF) Induces the Production of Cytokines in Vivo. British Journal of Haematology, 108, 848-853.
https://doi.org/10.1046/j.1365-2141.2000.01943.x
|
[25]
|
Mehta, H.M. and Corey, S.J. (2021) G-CSF, the Guardian of Granulopoiesis. Seminars in Immunology, 54, Article ID: 101515. https://doi.org/10.1016/j.smim.2021.101515
|
[26]
|
Schaue, D., Comin-Anduix, B., Ribas, A., Zhang, L., Goodglick, L., Sayre, J.W., Debucquoy, A., Haustermans, K. and McBride, W.H. (2008) T-Cell Responses to Survivin in Cancer Patients Undergoing Radiation Therapy. Clinical Cancer Research, 14, 4883-4890. https://doi.org/10.1158/1078-0432.CCR-07-4462
|
[27]
|
Kachikwu, E.L., Iwamoto, K.S., Liao, Y.P., DeMarco, J.J., Agazaryan, N., Economou, J.S., McBride, W.H. and Schaue, D. (2011) Radiation Enhances Regulatory T Cell Repre-sentation. International Journal of Radiation Oncology, Biology, Physics, 81, 1128-1135. https://doi.org/10.1016/j.ijrobp.2010.09.034
|
[28]
|
Demaria, S., Golden, E.B. and Formenti, S.C. (2015) Role of Local Radiation Therapy in Cancer Immunotherapy. JAMA Oncology, 1, 1325-1332. https://doi.org/10.1001/jamaoncol.2015.2756
|
[29]
|
Formenti, S.C. and Demaria, S. (2009) Systemic Effects of Local Radiotherapy. Lancet Oncology, 10, 718-726.
https://doi.org/10.1016/S1470-2045(09)70082-8
|
[30]
|
Spiotto, M., Fu, Y.X. and Weichselbaum, R.R. (2016) The Intersection of Radiotherapy and Immunotherapy: Mechanisms and Clinical Implications. Science Immunology, 1, eaag1266. https://doi.org/10.1126/sciimmunol.aag1266
|
[31]
|
Barker, H.E., Paget, J.T., Khan, A.A. and Harrington, K.J. (2015) The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence. Nature Re-views Cancer, 15, 409-425. https://doi.org/10.1038/nrc3958
|
[32]
|
Gupta, A., Probst, H.C., Vuong, V., Landsham-mer, A., Muth, S., Yagita, H., Schwendener, R., Pruschy, M., Knuth, A. and van den Broek, M. (2012) Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation. The Journal of Immunology, 189, 558-566. https://doi.org/10.4049/jimmunol.1200563
|
[33]
|
Zhao, H., Guo, M., Sun, X., Sun, W., Hu, H., Wei, L. and Ai, H. (2013) Effects of Recombinant Human Granulocyte Colony-Stimulating Factor on Central and Peripheral T Lymphocyte Reconstitution after Sublethal Irradiation in Mice. Journal of Radiation Research, 54, 83-91. https://doi.org/10.1093/jrr/rrs082
|
[34]
|
Cui, Y.H., Suh, Y., Lee, H.J., Yoo, K.C., Uddin, N., Jeong, Y.J., Lee, J.S., Hwang, S.G., Nam, S.Y., Kim, M.J., et al. (2015) Radiation Promotes Invasiveness of Non-Small-Cell Lung Cancer Cells through Granulocyte-Colony-Stimulating Factor. Oncogene, 34, 5372-5382. https://doi.org/10.1038/onc.2014.466
|
[35]
|
Kantoff, P.W., Higano, C.S., Shore, N.D., Berger, E.R., Small, E.J., Penson, D.F., Redfern, C.H., Ferrari, A.C., Dreicer, R., Sims, R.B., et al. (2010) Sipuleucel-T Immunotherapy for Cas-tration-Resistant Prostate Cancer. The New England Journal of Medicine, 363, 411-422. https://doi.org/10.1056/NEJMoa1001294
|
[36]
|
Higano, C.S., Schellhammer, P.F., Small, E.J., Burch, P.A., Nemunaitis, J., Yuh, L., Provost, N. and Frohlich, M.W. (2009) Integrated Data from 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Active Cellular Immunotherapy with Sipuleucel-T in Advanced Prostate Cancer. Cancer, 115, 3670-3679.
https://doi.org/10.1002/cncr.24429
|
[37]
|
Kohanbash, G., McKaveney, K., Sakaki, M., Ueda, R., Mintz, A.H., Amankulor, N., Fujita, M., Ohlfest, J.R. and Okada, H. (2013) GM-CSF Promotes the Immunosuppressive Activity of Glioma-Infiltrating Myeloid Cells through Interleukin-4 Receptor-α. Cancer Research, 73, 6413-6423. https://doi.org/10.1158/0008-5472.CAN-12-4124
|
[38]
|
Chen, L., Imamichi, S., Tong, Y., Sasaki, Y., Onodera, T., Nakamura, S., Igaki, H., Itami, J. and Masutani, M. (2021) A Combination of GM-CSF and Released Factors from Gamma-Irradiated Tumor Cells Enhances the Differentiation of Macrophages from Bone Marrow Cells and Their Anti-gen-Presenting Function and Polarization to Type 1. Medicines, 8, Article 35. https://doi.org/10.3390/medicines8070035
|
[39]
|
Shi, F., Wang, X., Teng, F., Kong, L. and Yu, J. (2017) Abscopal Effect of Metastatic Pancreatic Cancer after Local Radiotherapy and Granulocyte-Macrophage Colony-Stimulating Factor Therapy. Cancer Biology & Therapy, 18, 137-141. https://doi.org/10.1080/15384047.2016.1276133
|
[40]
|
Yu, T.W., Chueh, H.Y., Tsai, C.C., Lin, C.T. and Qiu, J.T. (2016) Novel GM-CSF-Based Vaccines: One Small Step in GM-CSF Gene Optimization, One Giant Leap for Human Vaccines. Human Vaccines & Immunotherapeutics, 12, 3020-3028. https://doi.org/10.1080/21645515.2016.1221551
|
[41]
|
Le, D.T., Wang-Gillam, A., Picozzi, V., Greten, T.F., Cro-cenzi, T., Springett, G., Morse, M., Zeh, H., Cohen, D., Fine, R.L., et al. (2015) Safety and Survival with GVAX Pan-creas Prime and Listeria Monocytogenes-Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 33, 1325-1333.
https://doi.org/10.1200/JCO.2014.57.4244
|
[42]
|
Golden, E.B., Chhabra, A., Chachoua, A., Adams, S., Donach, M., Fenton-Kerimian, M., Friedman, K., Ponzo, F., Babb, J.S., Goldberg, J., et al. (2015) Local Radiotherapy and Granulo-cyte-Macrophage Colony-Stimulating Factor to Generate Abscopal Responses in Patients with Metastatic Solid Tumours: A Proof-of-Principle Trial. The Lancet Oncology, 16, 795-803. https://doi.org/10.1016/S1470-2045(15)00054-6
|
[43]
|
Liu, M., Cai, X. and Zeng, Y. (2019) EP1.04-28 The Ab-scopal Effects of the Combination of Radiotherapy and GM-CSF for Patients with Metastatic Thoracic Cancers. Journal of Thoracic Oncology, 14, S980.
https://doi.org/10.1016/j.jtho.2019.08.2153
|
[44]
|
Jiang, H., Yu, K., Cui, Y., Ren, X., Li, M., Yang, C., Zhao, X., Zhu, Q. and Lin, S. (2021) Combination of Immunotherapy and Radiotherapy for Recurrent Malignant Gliomas: Results from a Prospective Study. Frontiers in Immunology, 12, Article 632547. https://doi.org/10.3389/fimmu.2021.632547
|
[45]
|
Kim, H.R., Kim, K.H., Kong, D.S., Seol, H.J., Nam, D.H., Lim, D.H. and Lee, J.I. (2015) Outcome of Salvage Treatment for Recurrent Glioblastoma. Journal of Clinical Neuroscience, 22, 468-473.
https://doi.org/10.1016/j.jocn.2014.09.018
|
[46]
|
Muenst, S., Läubli, H., Soysal, S.D., Zippelius, A., Tzankov, A. and Hoeller, S. (2016) The Immune System and Cancer Evasion Strategies: Therapeutic Concepts. Journal of Internal Medicine, 279, 541-562.
https://doi.org/10.1111/joim.12470
|
[47]
|
Weber, J. (2007) Review: Anti-CTLA-4 Antibody Ipilimumab: Case Studies of Clinical Response and Immune-Related Adverse Events. The Oncologist, 12, 864-872. https://doi.org/10.1634/theoncologist.12-7-864
|
[48]
|
Herbst, R.S., Soria, J.C., Kowanetz, M., Fine, G.D., Hamid, O., Gordon, M.S., Sosman, J.A., McDermott, D.F., Powderly, J.D., Gettinger, S.N., et al. (2014) Predictive Correlates of Response to the Anti-PD-L1 Antibody MPDL3280A in Cancer Patients. Nature, 515, 563-567. https://doi.org/10.1038/nature14011
|
[49]
|
Hodi, F.S., Lee, S., McDermott, D.F., Rao, U.N., Butterfield, L.H., Tarhini, A.A., Leming, P., Puzanov, I., Shin, D. and Kirkwood, J.M. (2014) Ipilimumab plus Sargramostim vs Ipili-mumab Alone for Treatment of Metastatic Melanoma: A Randomized Clinical Trial. JAMA, 312, 1744-1753. https://doi.org/10.1001/jama.2014.13943
|
[50]
|
Babiker, H., Brana, I., Mahadevan, D., Owonikoko, T., Calvo, E., Rischin, D., Moreno, V., Papadopoulos, K.P., Crittenden, M., Formenti, S., et al. (2021) Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. The Oncologist, 26, e1508-e1513. https://doi.org/10.1002/onco.13810
|
[51]
|
Zhao, X., Kong, Y. and Zhang, L. (2020) Anti-PD-1 Immunotherapy Combined with Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Negative Patient with Refractory Metastatic Esophageal Squamous Cell Carcinoma: A Case Report and Literature Review. Frontiers in Oncol-ogy, 10, Article 1625.
https://doi.org/10.3389/fonc.2020.01625
|
[52]
|
Kong, Y., Zhao, X., Xu, M., Pan, J., Ma, Y., Zou, L., Peng, Q., Zhang, J., Su, C., Xu, Z., et al. (2022) PD-1 Inhibitor Combined with Radiotherapy and GM-CSF (PRaG) in Patients with Metastatic Solid Tumors: An Open-Label Phase II Study. Frontiers in Immunology, 13, Article 952066. https://doi.org/10.3389/fimmu.2022.952066
|
[53]
|
He, H., Xu, T., Li, P., Jia, G., Li, X. and Song, Q. (2021) An-ti-PD-1 Immunotherapy Combined with Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient with Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Re-view. Frontiers in Oncology, 11, Article 782646.
https://doi.org/10.3389/fonc.2021.782646
|
[54]
|
Wang, Y., Li, W., Zuo, X., Min, K., Tang, Y., Chen, H., Wang, W. and Zhou, Y. (2023) Anti-PD-1 Immunotherapy Combined with Stereotactic Body Radiation Therapy and GM-CSF for the Treatment of Advanced Malignant PEComa: A Case Report. Frontiers in Oncology, 13, Article 1045119. https://doi.org/10.3389/fonc.2023.1045119
|
[55]
|
Yang, J., Xing, P., Kong, Y., Xu, M. and Zhang, L. (2023) PD-1 Inhibitor Combined with Radiotherapy and GM-CSF in MSS/pMMR Metastatic Colon Cancer: A Case Report. Fron-tiers in Oncology, 13, Article 1078915.
https://doi.org/10.3389/fonc.2023.1078915
|
[56]
|
Ni, J., Zhou, Y., Wu, L., Ai, X., Dong, X., Chu, Q., Han, C., Wang, X. and Zhu, Z. (2021) Sintilimab, Stereotactic Body Radiotherapy and Granulocyte—Macrophage Colony Stimu-lating Factor as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer: Safety Run-In Results of a Multicenter, Single-Arm, Phase II Trial. Radiation Oncology, 16, Article No. 177. https://doi.org/10.1186/s13014-021-01905-3
|